antifungal resistance – Page 17

Epidemiology and outcomes of Candida-associated osteoarticular infections: A multicentre retrospective study from Turkey

mycolabadmin

Researchers in Turkey studied 73 patients with rare bone and joint infections caused by Candida fungi over 10 years. They found that about half of the infections were caused by species other than the common C. albicans, with some showing resistance to fluconazole antibiotics. Surgical procedures to clean out infected tissue significantly improved patient recovery, while patients with diabetes had worse outcomes and recovered less completely.

Addressing filamentous fungi-related onychomycosis in the era of antifungal resistance: assessment of Zataria multiflora nanostructured lipid carrier topical gel in a double-blinded clinical trial

mycolabadmin

Nail fungal infections (onychomycosis) are difficult to treat, especially as fungi become resistant to standard antifungal medications. Researchers tested a new gel made from Zataria multiflora (Shirazi thyme) packaged in special nanoparticles that help the medicine penetrate the nail better. In a clinical trial comparing this gel to placebo, the Zataria multiflora treatment showed better results after just 2 weeks, with 70% of patients experiencing fungal cure compared to 55% with placebo.

First report of infections due to Candidozyma (formerly Candida) auris in Botswana, 2022–2024

mycolabadmin

Researchers in Botswana discovered the first documented cases of a dangerous fungal infection called Candidozyma auris in their country. This yeast was found in 10 patients at a major hospital, mostly in intensive care units, between 2022 and 2024. The fungus was resistant to common antifungal drugs like fluconazole but could still be treated with other medications. The findings highlight how this emerging pathogen is spreading across Africa and stress the importance of improved laboratory testing and disease monitoring in developing countries.

Computational analysis of missense mutations in squalene epoxidase associated with terbinafine resistance in clinically reported dermatophytes

mycolabadmin

Certain fungal skin infections are becoming resistant to terbinafine, a common antifungal medication, due to genetic mutations in an enzyme called squalene epoxidase. Using computer models and analysis tools, researchers identified which mutations most strongly reduce the drug’s effectiveness and where the protein changes occur. Four specific mutations were found to prevent terbinafine from binding to its target, offering insights that could help develop better antifungal treatments.

Breaking down biofilms across critical priority fungal pathogens: proteomics and computational innovation for mechanistic insights and new target discovery

mycolabadmin

Fungal infections like cryptococcal meningitis and invasive aspergillosis are becoming increasingly difficult to treat because fungi form protective structures called biofilms that resist our current medications. Researchers are using advanced techniques like mass spectrometry to identify the proteins that help fungi build these biofilms, combined with artificial intelligence tools to design new drugs that could break down these protective shields. This combined approach offers hope for developing better antifungal treatments that could save millions of lives.

Molecular epidemiology, diversity, and antifungal susceptibility profiles of clinical and environmental mucorales: a five-year multicenter study in Iran (2018–2023)

mycolabadmin

This study examined dangerous mold infections called mucormycosis that became more common during the COVID-19 pandemic, particularly in Iran. Researchers tested over 180 fungal samples from patients and soil to understand which types of molds cause infections and which antifungal medicines work best against them. They found that two medicines, amphotericin B and posaconazole, were most effective, while fungi from soil samples were often more resistant to treatment than those from infected patients. This research helps doctors choose the right treatments for patients with these serious infections.

Dermatophyte Treatment Failure: A Rapid Global Response to an Emerging Global Health Issue

mycolabadmin

Fungal skin infections affect nearly a billion people worldwide and are becoming increasingly difficult to treat due to growing resistance to common antifungal medications. A new species of fungus called T. indotineae, particularly resistant to the popular antifungal drug terbinafine, is spreading globally from India. To combat this emerging health crisis, doctors and health organizations are working together to create global registries and surveillance programs to track resistant infections and develop better treatment strategies.

Vesicle inhibition reduces Candida biofilm resistance

mycolabadmin

Researchers found that common FDA-approved drugs designed to block vesicle production in human cells can also reduce the protective matrix that Candida fungus builds around itself in biofilms. By combining these vesicle-blocking drugs with the antifungal fluconazole, the scientists were able to kill biofilm-forming Candida more effectively than either treatment alone. This discovery suggests a new approach to treating stubborn fungal infections on medical devices like catheters, potentially eliminating the need to surgically remove infected equipment.

Addressing Critical Fungal Pathogens Under a One Health Perspective: Key Insights from the Portuguese Association of Medical Mycology

mycolabadmin

This comprehensive study by Portugal’s mycology experts examines four dangerous fungi that cause severe infections: Aspergillus fumigatus, Candida auris, Candida albicans, and Cryptococcus neoformans. The research shows that Portugal’s hospitals have varying capabilities to diagnose and treat these infections, with some laboratories well-equipped and others lacking advanced diagnostic tools. The study found concerning increases in antifungal resistance and highlights that these fungi live in hospitals, water systems, soil, and even animals, emphasizing the need for integrated approaches connecting human, animal, and environmental health to better protect public health.

Neonatal Invasive Candidiasis: Current Concepts

mycolabadmin

Serious fungal infections (candidiasis) in newborns have become increasingly difficult to treat, especially in developing countries. The types of fungi causing these infections have changed dramatically, with many now resisting the standard fluconazole treatment. Modern medical care, like proper handwashing, environmental cleaning, and careful line care, is actually more effective at preventing these infections than giving preventive antifungal drugs. Healthcare providers need better tools for quickly identifying which fungal species is causing infection and which drugs will work against it.

Research Topic: antifungal resistance